Skip to main content
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Globe Newswire - Thu Jan 20, 2022

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome –

– KOMET-001 study to resume screening and enrollment of new patients –

Read more at globenewswire.com